FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
OpenAI is expanding ChatGPT's healthcare capabilities with a new integration that connects Epic electronic health records (EHRs) to ChatGPT for Healthcare and a plugin that gives care providers access to public healthcare data sources.
The Epic integration lets clinicians bring patient information into…
Updated migraine prevention guidance incorporates calcitonin gene-related peptide (CGRP)-targeted therapies and places greater emphasis on individualized treatment selection based on patient priorities.
Preventive therapy should be offered to those with at least 4 migraine days per month, at least 4 moderate-to-severe headache days per…
Attendees
Sponsors and Exhibitors
Contact us